Learn More
PURPOSE To study the efficacy of extensive coverage of the brain surface with subdural grids in defining extratemporal cortical areas amenable for resection in patients with refractory extratemporal epilepy (R-ExTE) and normal or nonlocalizing magnetic resonance imaging (MRI) scans. METHODS Sixteen patients with R-ExTE were studied. Eleven patients had(More)
PURPOSE The introduction of new technologies in the clinical practice have greatly decreased the number of patients submitted to invasive recordings. On the other hand, some patients with refractory temporal lobe epilepsy have normal MR scans or bilateral potentially epileptogenic lesions. This paper reports the results of invasive neurophysiology and(More)
BACKGROUND The low probability of curing high-risk prostate cancer (PC) with local therapy suggests the need to study modality of therapeutic approaches. To this end, a prospective phase II trial of neoadjuvant docetaxel (D) and complete androgen blockade (CAB) was carried out in high-risk PC patients. The primary end point was to detect at least 10% of(More)
PURPOSE To study the seizure's outcome in patients with refractory epilepsy and normal MRI submitted to resections including the rolandic cortex. METHODS Four adult patients were studied. All patients had motor or somatosensory simple partial seizures and normal MRI and were submitted to subdural grids' implantation with extensive coverage of the cortical(More)
RATIONALE The need for invasive monitoring in patients with refractory epilepsy has been greatly reduced by the introduction of new technologies such as PET, SPECT and MRI in the clinical practice. On the other hand, 10 to 30% of the patients with refractory epilepsy have non-localizatory non-invasive preoperative work-up results. This paper reports on the(More)
Results The incidence of POAF was 12.4% (2302 progressed without POAF Group I and 326 with POAFGroup II. Among the predictive factors for the occurrence of POAF, observed: age (Group I: 61.2 ± 9.38, group II: 66.8 ± 8.9, p <0.001); rate female: male ratio of 1:3; CRI (p=0.001), creatinine >/= 2.2mg/dl (p=0.002); COPD (p=0.001), ICC (p=0.004), EuroSCORE(More)
  • 1